ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 45 citations in OpenAlex.
- Trial
- Trial
- Risk of Bias Associated with Varying Sampling Strategies for External Comparator Cohorts for Single-Arm Trials: Insights from Aggressive Lymphoma.Clinical pharmacology and therapeutics · 2026Article
- Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.Haematologica · 2026Article
- LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.Blood advances · 2026Article
- LCR-modules: a collection of workflows for cancer genome analysis.Bioinformatics (Oxford, England) · 2026Article
- Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells.Nature communications · 2026Article
- Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.BMC medicine · 2026Article
- Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.Blood advances · 2026Article
- RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.bioRxiv : the preprint server for biology · 2026Article
- The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2026Article
- High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.Blood advances · 2025Article
- Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months.European journal of haematology · 2025Article
- Autologous stem cell transplantation from 2011 to 2022 in Japanese patients aged ≥ 65 years with relapsed or refractory diffuse large B-cell lymphoma.Annals of hematology · 2025Article
- Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma.Blood cancer journal · 2025Article
- Male Sex, B Symptoms, Bone Marrow Involvement, and Genetic Alterations as Predictive Factors in Diffuse Large B-Cell Lymphoma.International journal of molecular sciences · 2025Article
- A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma.Blood cancer discovery · 2025Article
- Audit of B-cell cancer genes.Blood advances · 2025Review
Corrections and comments
- Update of
Authors and funding
31 authors at 8 institutions in 2 countries.
Funding
Abstract
purposeDiffuse large B-cell lymphoma (DLBCL) is cured in more than 60% of patients, but outcomes remain poor for patients experiencing disease progression or relapse (refractory or relapsed DLBCL [rrDLBCL]), particularly if these events occur early. Although previous studies examining cohorts of rrDLBCL have identified features that are enriched at relapse, few have directly compared serial biopsies to uncover biological and evolutionary dynamics driving rrDLBCL. Here, we sought to confirm the relationship between relapse timing and outcomes after second-line (immuno)chemotherapy and determine the evolutionary dynamics that underpin that relationship. PATIENTS AND
methodsOutcomes were examined in a population-based cohort of 221 patients with DLBCL who experienced progression/relapse after frontline treatment and were treated with second-line (immuno)chemotherapy with an intention-to-treat with autologous stem-cell transplantation (ASCT). Serial DLBCL biopsies from a partially overlapping cohort of 129 patients underwent molecular characterization, including whole-genome or whole-exome sequencing in 73 patients.
resultsOutcomes to second-line therapy and ASCT are superior for late relapse (>2 years postdiagnosis) versus primary refractory (<9 months) or early relapse (9-24 months). Diagnostic and relapse biopsies were mostly concordant for cell-of-origin classification and genetics-based subgroup. Despite this concordance, the number of mutations exclusive to each biopsy increased with time since diagnosis, and late relapses shared few mutations with their diagnostic counterpart, demonstrating a branching evolution pattern. In patients with highly divergent tumors, many of the same genes acquired new mutations independently in each tumor, suggesting that the earliest mutations in a shared precursor cell constrain tumor evolution toward the same genetics-based subgroups at both diagnosis and relapse.
conclusionThese results suggest that late relapses commonly represent genetically distinct and chemotherapy-naïve disease and have implications for optimal patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.